Preview

Научно-практическая ревматология

Расширенный поиск

АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ ПРИ РЕВМАТОИДНОМ АРТРИТЕ

https://doi.org/10.14412/1995-4484-2011-574

Полный текст:

Список литературы

1. <div><p>Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой М.: ГЭОТАР-Медиа, 2008.</p><p>Meune C., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology 2009; 48(10): 1309-13.</p><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. M.: ГЭОТАР-Медиа, 2010; 678-702.</p><p>Peters M.J., Symmons D.P., McCarey D.W. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2010; 69(2): 325-31.</p><p>Van Halm V.P., Peters M.-J., Voskuyl A.E. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009; 68: 1395-400.</p><p>Российские рекомендации по диагностике и лечению артериальной гипертензии. В кн.: Национальные клинические рекомендации: Сборник. Под ред. Р.Г. Оганова. 2-е изд. М.: Силицея-Полиграф, 2009; 292-332.</p><p>Wolfe F., Freundlich В., Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthri- tis. J Rheumatol 2003; 30: 36-40.</p><p>Assous N., Touze E., Meune C. et al. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Joint Bone Spine 2007; 74: 66-72.</p><p>Roman M.J., Moeller E., Davis A. et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006; 144: 249-56.</p><p>Dessein P.H., Tobias M., Veller M.G. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33: 2425-32.</p><p>Panoulas V.F., Douglas K.M.J., Milionis H.J. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 2007; 46: 1477-82.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al.; QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther 2008; 1: 30.</p><p>Попкова Т.В., Новикова Д.С., Писарев В.В. и др. Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите. Науч.-практич. ревматол. 2009; 3: 4-11</p><p>Han C., Robinson D.W., Hackett M.V. et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-72.</p><p>Никитина Н.М., Ребров А.П. Артериальная гипертония у больных ревматоидным артритом. Рацион. фармакотер. в кардиологии 2009; 3: 67-70.</p><p>Del Rincon I., Freeman G.L., Haas R.W. et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthr Rheum 2005; 52: 3413-23.</p><p>Dessein P.H., Joffe B.I., Stanwix A.E. et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31: 867-74.</p><p>Корягина Н.В., Мясоедова С.Е., Лебедева О.В. и др. Особенности артери- альной гипертонии при ревматоидном артрите. Сборник материалов V съезда ревматологов России. М., 2009; с. 57.</p><p>Хусаинова Д.К., Терегулов Ю.Э., Салихов И.Г. Эндотелиальная дисфункция и артериальная гипертензия у больных ревматоидным артритом. Науч.-практич. ревматол. 2006; 3: 27-32.</p><p>Аршин Е.В. Эпидемиология артери- альной гипертензии у больных ревмато- идным артритом. Науч.-практич. ревматол. 2005; 5: 23-6.</p><p>Оганов Р.Г., Масленникова Г.Я. Сердечно-сосудистые заболевания в Российской Федерации во второй половине ХХ столетия: тенденции, возможные причины, перспективы. Кардиология 2000; 6: 4-9.</p><p>Лазебник Л.Б., Комиссаренко И.А., Милюкова О.М. Систолическая артериальная гипертония у пожилых. Рус. мед. журн. 1997; 5(20): 28-36.</p><p>Jorgensen K.T., Pedersen B.V., Jacobsen S. et al. National cohort study of reproductive risk factors for rheumatoid arthritis in Denmark: a role for hyperemesis, gestational hypertension and pre-eclampsia? Ann Rheum Dis 2010; 69(2): 358-63.</p><p>Rodriguez L.A., Tolosa L.B., Ruigomez A. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 2009; 38(3): 173-7.</p><p>Panoulas V.F., Metsios G.S., Pace A.V. et al. Hypertension in rheumatoid arthritis. Rheumatology 2008; 47: 1286-98.</p><p>Savoia C., Schiffrin E.L. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 2: 152-8.</p><p>Savoia C., Schiffrin E.L. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007; 112: 375-84.</p><p>Blake G.J., Rifai N., Buring J.E. et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-9.</p><p>Engstrom G., Lind P., Hedblad В. et al. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002; 33: 2744-9.</p><p>De Ciuceis C., Amiri F., Brassard P. et al. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 2106-13.</p><p>Chae C.U., Lee R.T., Rifai N. et al. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403.</p><p>Bermudez E.A., Rifai N., Buring J. et al. Interrelationships among circulating interleukin-6, C-reactive protein and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668-73.</p><p>Schillaci G., Pirro M., Gemelli F. et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-6.</p><p>Ощепкова Е.В., Дмитриев В.А., Титов B.H. и др. Показатели неспецифического воспаления у больных гипертонической болезнью. Тер. арх. 2007; 12: 18-25</p><p>Bautista L.E., Vera L.M., Arenas I.A. et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6 and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19: 149-54</p><p>Stumpf C., John S., Jukic J. et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005; 23: 995-1000.</p><p>Stumpf C., Jukic J., Yilmaz A. et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur J Clin Invest 2009; 39(1): 31-6.</p><p>Abramson J.L., Weintraub W.S., Vaccarino V. et al. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002; 39: 197-202.</p><p>Kim K., Lee J.H., Chang H.J. et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 2008; 72: 293-8.</p><p>Chrysohoou C., Pitsavos C., Panagiotakos D.B. et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-73</p><p>Engström G., Janzon L., Berglund G. et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22: 2054-</p><p>Sesso H., Buring J., Rifai N. et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290(22): 2945-51.</p><p>Niskanen L., Laaksonen D.E., Nyysso K. Inflammation, abdominal obesity and smoking as predictors of hypertension. Hypertension 2004; 44: 859-65.</p><p>Pitsavos C., Chrysohoou C., Panagiotakos D.B. et al. Abdominal obesity and inflammation predicts hypertension among prehypertensive men and women: the ATTICA Study. Heart Vessels 2008; 23(2): 96-103.</p><p>Heffernan K.S., Karas R.H., Kuvin J.T. Carotid artery stiffness, high-density lipoprotein cholesterol and inflammation in men with pre-hypertension. J Hum Hypertens 2009; 9: 590-6.</p><p>Lieb W., Larson M.G., Benjamin E. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. J Circul 2009; 119: 37-43.</p><p>De Silva D.A., Woon F.P., Gan H.Y. Arterial stiffness, metabolic syndrome and inflammation amongst Asian ischaemic stroke patients. Eur J Neurol 2008; 15: 872-5.</p><p>Lee Y.J., Lee J.W., Kim J.K. Elevated white blood cell count is associated with arterial stiffness. Nutr Metab Cardiovasc Dis 2009; 19: 3-7.</p><p>Schnabel R., Larson M.G., Dupuis J. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. J Hypertension 2008; 51: 1651-7.</p><p>Nakhai-Pour H.R., Grobbee D.E., Bots M.L. C-reactive protein and aortic stiffness and wave reflection in middle-aged and elderly men from the community. J Hum Hypertens 2007; 21: 949-55.</p><p>Tsioufis C., Dimitriadis K., Selima M. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 2007; 28: 1162-9.</p><p>Pietri P., Vyssoulis G., Vlachopoulos C. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006; 24: 2231-8.</p><p>Mahmud A., Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118-22.</p><p>Kullo I.J., Seward J.B., Bailey K.R. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens 2005; 18: 1123-9.</p><p>Nagano M., Nakamura M., Sato K. Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis 2005; 180: 189-95.</p><p>Pirro M., Schillaci G., Savarese G. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia. Eur J Clin Invest 2004; 34: 335-41.</p><p>Mattace-Raso F.U., van der Cammen T.J., van der Meer I.M. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis 2004; 176: 111-6.</p><p>Yasmin Y., McEniery C.M., Wallace S. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004; 24: 969-74.</p><p>Tsai W.C., Lin C.C., Huang Y.Y. Association of increased arterial stiffness and inflammation with proteinuria and left ventricular hypertrophy in non-diabetic hypertensive patients. Blood Press 2007; 16: 270-5.</p><p>Новикова Д.С., Попкова Т.В., Мач Э.С., Насонов Е.Л. Ригидность артерий - интегральный показатель сердечно-сосудистого риска у больных ревматоидным артритом. Науч.-практич. ревматол. 2009; 5: 38-48.</p><p>Crilly M.A., Clark H.J., Kumar V. et al. Relationship between arterial stiffness and Stanford Health Assessment Questionnaire disability in rheumatoid arthritis patients without overt arterial disease. J Rheumatol 2010; 37(5): 946-52.</p><p>Pearson T.A., Mensah G.A., Alexander R.W. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.</p><p>Насонов Е.Л., Панюгова Е.В., Александрова Е.Н. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53-62.</p><p>Александрова Е.Н., Новиков А.А., Насонов Е.Л. Высокочувствительные методы определения С-реактивного белка (обзор литературы). Клин. лаб. диагностика 2004; 11: 16-8.</p><p>Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 2009; 48: 11-22.</p><p>Goodson N.J., Symmons D.P., Scott D.G. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup of primary care-based inception cohort. Arthr Rheum 2005; 52: 2293-9.</p><p>Poole C.D., Conway P., Currie C.J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortali- ty in chronic immune-mediated inflamma- tory disease managed in UK general prac- tice. Rheumatology 2009; 48: 78-82.</p><p>. Savoia C., Schiffrin E.L. Reduction of C-reactive protein and the use of antihypertensive. Vascular Health and Risk Management 2007; 3(6): 975-83.</p><p>Wang C.H., Li S.H., Weisel R.D. et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-90.</p><p>Srikumar N., Brown N.J., Hopkins P.N. et al. PAI-1 in human hypertension: relation to hypertensive groups. Am J Hypertens 2002; 15: 683-90.</p><p>Poli K.A., Tofler G.H., Larson M.G. et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-9.</p><p>Dawson S., Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-17.</p><p>Gasparyan A.Y., Stavropoulos-Kalinoglou A., Toms T.E. et al. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets 2010; 9(1): 45-50</p><p>Tomasson G., Aspelund T., Jonsson T. et al. The effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010; 69(9): 1649-54. Goodson N.I., Willes N.J., Lunt N.C. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum 2002; 46: 2010-9.</p><p>Новикова Д.С., Попкова Т.В., Александрова Е.Н. и др. Роль антител к циклическому цитруллинированному пептиду (АЦЦП) и модифицированному цитруллинированному виментину (АМЦВ) в развитии атеросклеротического поражения сосудов при ревматоидном артрите. Сб. матер. V съезда ревматологов России. М., 2009; 57.</p><p>Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical athero- sclerosis in patients with rheumatoid arthri- tis. Ann Rheum Dis 2008; 67: 724-5.</p><p>Lopez-Longo F.J., Oliver-Minarro D., de la Torre I. et al. Association between anticyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum 2009; 61: 419-24.</p><p>Giles J.T., Malayeri A.A., Fernandes V. et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthr Rheum 2010; 62(4): 940-51.</p><p>Dai G., Kaazempur-Mofrad M.R., Natarajan S. et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and resistant regions of human vasculature. Proc Natl Acad Sci USA 2004; 101: 14871-6.</p><p>Pauletto P., Ratazzi M. Inflammation and hypertension: the search for a link. Nephrol Dial Transplant 2006; 21: 850-3.</p><p>Oparil S., Zaman A.M., Calhoun D.A. Pathogenesis of Hypertension. Ann Intern Med 2003; 139: 761-6.</p><p>Puato M., Faggin E., Favaretto E. et al. Prevalence of fetal-types mooth muscle cells in the media of microvessels from 79. hypertensive patients. Hypertension 2004; 44: 191-4.</p><p>Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin. Rheumatology 2005; 44: 1473-82.</p><p>Guzik T.J., Hoch N.E., Brown K.A. et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Engl Med 2007; 204: 2449-60.</p><p>Elencov I.J., Wilder R.L., Chroussos G.P. et al. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.</p><p>Elenkov I.J., Chrousos G.P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann NY Acad Sci 2002; 966: 290-303.</p><p>Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289-96.</p><p>Thayer J.F. Vagal tone and the inflammatory reflex. Cliv Clin J Med 2009; 76(2): s23-s26.</p><p>Tracey K.J., Ulloa L. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-21.</p><p>Holman A.J., Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Auton Neurosci 2008; 143(1-2): 58-67.</p><p>Dickens C., Psycii M.R., Jackson J. Association of depression and rheumatoid arthritis. Psychosomatics 2003; 44(3): 209-15.</p><p>Treharne G.J., Hale E.D., Lyons A.C. et al. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. Rheumatology 2005; 44: 241-6.</p><p>Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф. и др. Распространенность психических нарушений у больных системной красной волчанкой: связь с активностью заболевания и сопутствующими хроническими расстройствами. Тер. арх. 2009; 6: 10-6.</p><p>Wolfe F., Michaud K., Li T., Katz R.S. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010; 37(2): 305-15.</p><p>Ang D.C., Choi H., Kroenke K., Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1013-9.</p><p>Новикова Д.С., Попкова Т.В., Лисицына Т.А., Насонов Е.Л. Перспективы определения вариабельности ритма сердца и длительности интервала QT при ревматоидном артрите и системной красной волчанке. Науч.-практич. ревматол. 2010; 5: 54-66.</p><p>Fagard R.H., Stolarz K., Kuznetsova T. et al. Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. J Hypertens 2007; 25(11): 2280-5.</p><p>Huikuri H., Ylitalo A., Pikkujamsa S.M. et al. HR variability in sistemic hypertension. Am J Cardiol 1996; 77(12): 1073-7.</p><p>Новикова Д.С., Попкова Т.В., Маркелова Е.И. и др. Клиническое значение оценки вариабельности ритма сердца у больных ревматоидным артритом. Клин. мед. 2009; 1: 27-32.</p><p>Дмитриев В.А., Ощепкова Е.В., Титов В.Н. и др. С-реактивный белок и интерлейкин-6 при поражении органов-мишеней на ранних стадиях у больных гипертонической болезнью. Кардиол. вестн. 2007; 2: 55-61.</p><p>Panoulas V.F., Toms T.E., Metsios G.S. Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate. Atherosclerosis 2010; 209(1): 255-60. RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 2009; 8(23): 3925-42.</p><p>K.M., Panoulas V.F., Douglas Smith J.P. et al. Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 2009; 48(2): 113-8.</p><p>Panoulas V.F., Smith J.P., Stavropoulos-Kalinoglou A. et al. Lack of an association of GNB3 C825T polymorphism and blood pressure in patients with rheumatoid arthritis. Clin Exp Hypertens 2009; 31(5): 428-39.</p><p>Panoulas V.F., Douglas K.M., Smith J.P. et al. Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis. Clin Exp Hypertens 2009; 31(2): 93-104.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009; 168 с.</p><p>Aw T.-J., Haas S.J., Liew D. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-6.</p><p>Попкова Т.В., Хелковская А.Н., Мач Э.С. и др. Сердечно-сосудистые заболевания при ревматоидном артрите. Тер. арх. 2007; 5: 9-14.</p><p>Chung C.P., Oeser A., Joseph F. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196(2): 756-63.</p><p>Gonzalez-Gay M.A., De Matias J.M., Gonzalez-Juanatey C. et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.</p><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Кардиоваскулярные факторы риска при ревматических заболеваниях: связь с воспалением. Consilium medicum 2010; 2: 112-8.</p><p>Sidiropoulos P.I., Karvounaris S.A., Boumpas D.T. Metabolic syndrome in rheumatic disease: epidemiology, pathophysiology, and clinical implications. Arthr Res Ther 2008; 10: 207.</p><p>Dessein P.H., Gonzalez-Gay M.A., Woodiwiss A.J. et al. The impact of the metabolic syndrome on cardiovascular risk and disease in rheumatoid arthritis. Future Reumatol 2008; 3(4): 335-49.</p><p>Елисеев М.С., Барскова В.Г., Ильиных Е.В., Насонова В.А. Синдром инсулинорезистентности и подагра: исторический аспект и современное состояние проблемы. Клин. геронтол. 2005; 11(4): 30-41.</p><p>Kim S.Y., Guevara J.P., Kim K.M. et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthr Reum 2009; 7: 885-92.</p><p>Panoulas V.F., Milionis H.J. Douglas K.M. et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology 2007; 9: 1466-70.</p><p>Mikuls T.R. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17: 729-52.</p><p>Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Применение диклофенака и целебрекса у пациентов с артериальной гипертонией, остеоартрозом и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Новости доказательной медицины. www.OSSN.ru &lt;http://www.OSSN.ru&gt;</p><p>Goodson N.J., Brookhart M.A., Symmons D.P.M. Non-steroidal antiinflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 3: 369-72.</p><p>Solomon D.H., Glynn R.J., Rothman K.J. Subgroup analyses to determine cardiovascular risk associated with non-steroidal antiinflammatory drugs and coxibs in specific patient groups. Arthr Rheum 2008; 59(8): 1097-104</p><p>Koo B.K., Kim Y.-S., Park K.-W. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 2007; 370: 567-74.</p><p>Гаврилова С.А., Липина Т.В., Загиддуллин Т.Р. и др. Протекторное действие лорноксикама на развитие инфаркта миокарда у крыс в условиях ишемии и ишемии-реперфузии. Кардиология 2008; 12: 42-8.</p><p>Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthr Rheum 2006; 54: 3790-8.</p><p>Scott D.L., Smolen J.S., Kalden J.R. et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913-23</p><p>Strand V., Cohen S., Schiff M. et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.</p><p>ohen S., Cannon G.W., Schiff M. et al. Two-year, Cblinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial investigator group. Arthr Rheum 2001; 44: 1984-92.</p><p>Rozman В., Praprotnik S., Logar D. et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61: 567-9.</p><p>Fox R.I., Herrmann M.L., Frangou C.G. et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93: 198-208.</p><p>Li E.K., Tam L.S., Tomlinson В. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004; 26: 447-59.</p><p>Textor S.C., Canzanello V.J., Taler S.J. et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-93.</p><p>Taler S.J., Textor S.C., Canzanello V.J., Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 1999; 20: 437-49.</p><p>Kvien T.K., Zeidler H.K., Hannonen P. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 2002; 61(6): 511-6.</p><p>Dijkmans В., Gerards A. Cyclosporin in rheumatoid arthritis: monitoring for adverse effects and clinically significant drug interactions. BioDrugs 1998; 10: 437-45.</p><p>Schrama Y.C., Koomans H.A. Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function. J Hypertens 1998; 16: 33-8.</p><p>Robert N., Wong G.W., Wright J.M. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 20(1): CD007893.</p><p>Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-8.</p><p>Dixon W.G., Watson K.D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthr Rheum 2007; 56: 2905-12.</p><p>Hurlimann D., Forster A., Noll G. et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.</p><p>Gonzalez-Juanatey C., Testa A., Garcia-Castelo A. et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthr Rheum 2004; 51: 447-50.</p><p>Van Doornum S., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005; 44: 1428-32.</p><p>Angel K., Provan S.A., Agewall S. et al. TNF-alpha antagonists reduce arterial stiffness in patients with rheumatoid arthritis and related arthropaties: a controlled study. Ann Rheum Dis 2008; 67(Suppl. II): 160.</p><p>Cypiene A., Laucevicius A., Venalis A. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc 2007; 50: 119-22.</p><p>Maki-Petaja K.M., Hall F.C., Booth A.D. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circul 2006; 114: 1185-92.</p><p>Del Porto F., Lagana В., Lai S. et al. Response to anti-tumor necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 2007; 46: 1111-5.</p><p>Di Micco P., Ferrazzi P., Libre L. et al. Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis. Int J Gen Med 2009; 30(2): 141-4.</p><p>Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circul 2004; 109: 1594-602.</p><p>Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circul 2003; 107: 3133-40.</p><p>Danila M.I., Patkara N.M., Curtisa J.R. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser? Curr Opin Rheum 2008; 20: 327-33.</p><p>Carmona L., Descalzo M.A., Perez-Pampin E. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-5</p><p>Listing J., Strangfeld A., Kekow J. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthr Rheum 2008; 58: 667-77.</p><p>Wasserman M.J., Weber D.A., Guthrie J.A. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004; 10: 1912-7.</p><p>Lequerre T., Vittecoq O., Klemmer N. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006; 7: 1307-14.</p><p>Lazzerini P.E., Acampa M., Hammoud M. Arrhythmic risk during acute infusion of infliximab: a prospective, singleblind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheum 2008; 10: 1958-65.</p><p>Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-7</p><p>Wolfe F., Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis. A cohort and nested case-control analysis. Arthr Rheum 2008; 58(9): 2612-21</p><p>Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthr Rheum 2006; 55: 531-6.</p><p>Hafstrom I., Rohani M., Deneberg S. et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis - a randomized study. J Rheumatol 2007; 34: 1810-6.</p><p>Georgiadis A.N., Papavasiliou E.C., Lourida E.S. et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthr Res Ther 2006; 8: 82.</p><p>Davis J.M., Kremers M.H., Crowson C.S. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthr Rheum 2007; 56: 820-30.</p><p>Sihnoven S., Korpela M., Mustonen J. et al. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 2006; 33: 1740-6.</p><p>Munro R., Morrison E., McDonald A.G. et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.</p><p>Wallace D.J., Metzger A.L., Stecher V.J. et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-6</p><p>Bili A., Newman E.D., Kirchner H.L. Hydroxychloroquine use reduces risk of dia- betes in rheumatoid arthritis patients. Arthr Rheum 2008; 58(Suppl. 9): 456.</p><p>Mogun H., Schneeweiss S. Hydroxychloroquine is associated with reduced risk of diabetes among older adults with rheumatoid arthritis. Arthr Rheum 2008; 58(Suppl. 9): 268.</p><p>Wasco M.C., Hubert H., Lingala В. All- cause mortality in RA. Arthr Rheum 2008; 58(Suppl. 9): 276.</p><p>Rho Y.H., Oeser A., Chung C.P. et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009; 2(2): 34-40.</p><p>Toms T.E., Panoulas V.F., Douglas K.M. et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann Rheum Dis 2010; 4: 683-8.</p><p>Stavropoulos-Kalinoglou A., Metsios G.S., Koutedakis Y. et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-21.</p><p>Dickinson H.O., Mason J.M., Nicolson D.J. et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24: 215-33.</p><p>Metsios G.S., Stavropoulos-Kalinoglou A., Veldhuijzen van Zanten J.J. et al. Rheumatoid arthritis, cardiovascular disease and physical exercise: systematic review. Rheumatology 2008; 47: 239-48.</p><p>Appel L.J., Brands M.W., Daniels S.R. et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47: 296-308.</p><p>Scoldstem L., Hagfors L., Johannson J. et al. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 208-14.</p><p>Hayashi T., Tsumura K., Suematsu C. et al. Walking to work and the risk for hypertension in men: the Osaka Health Survey. Ann Intern Med 1999; 131: 21-6.</p><p>Hakkinen A., Hakkinen K., Hannonen P. Effects of strength training on neuromuscular function and disease activity in patients with recent-onset inflammatory arthritis. Scand J Rheumatol 1994; 23: 237-42.</p><p>Van den Ende C.H., Breedveld F.C., Le Cessie S. et al. Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2000; 59: 615-21</p><p>Van den Ende C.H., Hazes J.M., Le Cessie S. et al. Comparison of high and low intensity training in well controlled rheumatoid arthritis. Results of a randomized clinical trial. Ann Rheum Dis 1996; 55: 798-805.</p><p>Metsios G.S., Stavropoulos-Kalinoglou A., Nevill A.M. et al. Smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 70-3.</p><p>Abhishek A., Butt S., Gadsby K. et al. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol 2010; 1: 15-8.</p><p>Neal В., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356: 1955-64.</p><p>Napoli M.D., Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C- reactive protein in patients with first-ever ischemic stroke. Stroke 2003; 34: 2922-9</p><p>Sanz-Rosa D., Oubina M.P., Cediel E. et al. Effect of AT1receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol 2005; 288: 111-5.</p><p>Luvara G., Pueyo M.E., Philippe M. et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998; 18(9): 1408-1</p><p>Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circul 2004; 110: 1103-7.</p><p>Schiefer В., Bunte C., Witte J. et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. JACC 2004; 44: 362-8.</p><p>Dandona P., Dhindsa S., Ghanim H. et al. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21: 20-7.</p><p>Flammer A.J., Sudano I., Hermann F. et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circul 2008; 117: 2262-9.</p><p>Dekkers J.C., Geenen R., Godaert G.L. et al. Elevated sympathetic nervous system activity in patients with recently diagnosed rheumatoid arthritis with active disease. Clin Exp Rheumatol 2004; 22: 63-70.</p><p>Кардиология: национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007; 1232 с.</p><p>Yoshii T., Iwai M., Li Z. et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 6: 457-66.</p><p>Shurtz-Swirski R., Farah R., Sela S. et al. The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients. Harefuah 2006; 12: 895-</p><p>Yao R., Cheng X., Liao Y.H. et al. Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesterol-diet apolipoprotein E-knockout mice. J Cardiovasc Pharmacol 2008; 2: 188-</p><p>Ежов М.В. Артериальная гипертония и применение нестероидных противовоспалительных препаратов: преимущества амлодипина. Системные гипертензии 2009; 1: 23-5.</p><p>Cohen J.D. Overview of physiology, vascular biology and mechanisms of Hypertension. J Manag Care Pharm 2007; 13(5): 6-8.</p><p>Bakris G.L. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Manag Care Pharm 2007; 13(5): 9-12.</p><p>Ситникова М.Ю., Иванов С.Г., Хмельницкая К.А. Плейотропные эффекты β-адреноблокаторов в терапии сердечно-сосудистых заболеваний: влияние на перекисное окисление липидов, свойства эндотелия и эволюцию атеросклероза. Кардиология 2009; 6: 61-6.</p></div><br />


Для цитирования:


Новикова Д.С., Попкова Т.В., Насонов Е.Л. АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ ПРИ РЕВМАТОИДНОМ АРТРИТЕ. Научно-практическая ревматология. 2011;49(3):52-68. https://doi.org/10.14412/1995-4484-2011-574

For citation:


Novikova D.S., Popkova T.V., Nasonov E.L. Arterial hypertension in rheumatoid arthritis. Rheumatology Science and Practice. 2011;49(3):52-68. (In Russ.) https://doi.org/10.14412/1995-4484-2011-574

Просмотров: 2103


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)